10-Q quarterly report · filed Nov 5, 2026

ICU MEDICAL INC/DE (ICUI) Q3 2026 10-Q Quarterly Report

Short answer

ICU MEDICAL INC/DE (ICUI) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $560M (up 4.4% year over year) with net income of $8M.

Q3 2026 key financials · XBRL

Revenue
$560M
+4.4% YoY · +1.6% QoQ
Net income
$8M
+120.0% YoY · +170.3% QoQ
Operating margin
9.3%
Gross margin
41.9%
EPS (diluted)
$1.06
+857.1% YoY · +39.5% QoQ

Source: XBRL data from the ICU MEDICAL INC/DE (ICUI) Q3 2026 10-Q on SEC EDGAR. USD.

ICU MEDICAL INC/DE Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $560.4M, up from $537.0M YoY, driven by Infusion Systems growth
  • Gross margin 41.9% vs 37.4% YoY, aided by $10.4M tariff refunds and price increases
  • Best segment: Infusion Systems revenue $192.5M, up 10.7%; worst: Vital Care $69.5M, down 10.9%
  • Cash $301.8M vs $308.0M at December 31, 2025; operating cash flow $218.6M year-to-date
  • Capital deployment: $120.6M Term Loan B prepayments; 2026 capital expenditure outlook reduced to approximately $75M
  • Near-term headwinds: tariffs, freight costs, oil prices, inflation, foreign exchange volatility and anticipated joint-venture impairment charges

Risk Factors

  • No material changes to 2025 Form 10-K risk factors disclosed
  • Carried-forward risks include medical-device regulatory compliance and product liability exposure
  • Carried-forward risks include supply-chain disruption affecting device manufacturing
  • Carried-forward risks include competition and healthcare-provider purchasing pressure
  • Carried-forward risks include liquidity, debt, and foreign-currency exposures

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ICU MEDICAL INC/DE quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.